{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:12:49Z","timestamp":1770221569496,"version":"3.49.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-16066707"],"award-info":[{"award-number":["RS-2025-16066707"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40261-025-01513-z","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:42:43Z","timestamp":1766508163000},"page":"159-172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetics of Amlodipine and Telmisartan Following Oral Administration of a Single-Pill Fixed-Dose Combination in Healthy Korean Male Subjects"],"prefix":"10.1007","volume":"46","author":[{"given":"Eunji","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Kyung","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo Ram","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seh Hyon","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woojin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4595-9376","authenticated-orcid":false,"given":"Christine E.","family":"Staatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9538-0565","authenticated-orcid":false,"given":"In-hwan","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"1513_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018912","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018912.","journal-title":"Circulation"},{"issue":"33","key":"1513_CR2","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","journal-title":"Eur Heart J"},{"key":"1513_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018. https:\/\/doi.org\/10.1161\/HYP.0000000000000066.","journal-title":"Hypertension"},{"key":"1513_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae178","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178.","journal-title":"Eur Heart J"},{"key":"1513_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14709","author":"JG Wang","year":"2023","unstructured":"Wang JG, Palmer BF, Vogel Anderson K, Sever P. Amlodipine in the current management of hypertension. J Clin Hypertens (Greenwich). 2023. https:\/\/doi.org\/10.1111\/jch.14709.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1513_CR6","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.632367","author":"M Destro","year":"2011","unstructured":"Destro M, Cagnoni F, Dognini GP, Galimberti V, Taietti C, Cavalleri C, et al. Telmisartan: just an antihypertensive agent? A literature review. Expert Opin Pharmacother. 2011. https:\/\/doi.org\/10.1517\/14656566.2011.632367.","journal-title":"Expert Opin Pharmacother"},{"key":"1513_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116169","volume":"171","author":"M Imenshahidi","year":"2024","unstructured":"Imenshahidi M, Roohbakhsh A, Hosseinzadeh H. Effects of telmisartan on metabolic syndrome components: a comprehensive review. Biomed Pharmacother. 2024;171:116169. https:\/\/doi.org\/10.1016\/j.biopha.2024.116169.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"1513_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1083","volume":"11","author":"RP Rothlin","year":"2023","unstructured":"Rothlin RP, Pelorosso FG, Duarte M, Nicolosi L, Ignacio FC, Salgado MV, et al. Telmisartan and losartan: the marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19. Pharmacol Res Perspect. 2023;11(2):e01083. https:\/\/doi.org\/10.1002\/prp2.1083.","journal-title":"Pharmacol Res Perspect"},{"key":"1513_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2010.00397.x","author":"AH Gradman","year":"2011","unstructured":"Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Clin Hypertens (Greenwich). 2011. https:\/\/doi.org\/10.1111\/j.1751-7176.2010.00397.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"1513_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","volume":"77","author":"G Parati","year":"2021","unstructured":"Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021;77(2):692\u2013705. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15781.","journal-title":"Hypertension"},{"issue":"5\u20136","key":"1513_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1080\/08037050802565171","volume":"17","author":"SE Kjeldsen","year":"2008","unstructured":"Kjeldsen SE, Weber M, Oparil S, Jamerson KA. Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective. Blood Press. 2008;17(5\u20136):260\u20139. https:\/\/doi.org\/10.1080\/08037050802565171.","journal-title":"Blood Press"},{"issue":"2","key":"1513_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2174\/1573402118666220627120254","volume":"18","author":"SM Farag","year":"2022","unstructured":"Farag SM, Rabea HM, Abdelrahim ME, Mahmoud HB. Target blood pressure and combination therapy: focus on angiotensin receptor blockers combination with either calcium channel blockers or beta blockers. Curr Hypertens Rev. 2022;18(2):138\u201344. https:\/\/doi.org\/10.2174\/1573402118666220627120254.","journal-title":"Curr Hypertens Rev"},{"issue":"4","key":"1513_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1751-7176.2009.00098.x","volume":"11","author":"TW Littlejohn","year":"2009","unstructured":"Littlejohn TW, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R, et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich). 2009;11(4):207\u201313. https:\/\/doi.org\/10.1111\/j.1751-7176.2009.00098.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"1513_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2165\/11204880-000000000-00000","volume":"10","author":"MD Moen","year":"2010","unstructured":"Moen MD. Telmisartan\/amlodipine. Am J Cardiovasc Drugs. 2010;10(6):401\u201312. https:\/\/doi.org\/10.2165\/11204880-000000000-00000.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"1513_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40885-021-00184-0","volume":"28","author":"B-J Kim","year":"2022","unstructured":"Kim B-J, Cho K-I, Kwon HM, Choi S-M, Yoon C-H, Lim SW, et al. Effect of a fixed-dose combination of telmisartan\/S-amlodipine on circadian blood pressure compared with telmisartan monotherapy: TENUVA-BP study. Clin Hypertens. 2022;28(1):7. https:\/\/doi.org\/10.1186\/s40885-021-00184-0.","journal-title":"Clin Hypertens"},{"issue":"1","key":"1513_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000175050","volume":"80","author":"DR Abernethy","year":"1992","unstructured":"Abernethy DR. Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology. 1992;80(1):31\u20136. https:\/\/doi.org\/10.1159\/000175050.","journal-title":"Cardiology"},{"issue":"1","key":"1513_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1365-2125.1986.tb02874.x","volume":"22","author":"JK Faulkner","year":"1986","unstructured":"Faulkner JK, McGibney D, Chasseaud LF, Perry JL, Taylor IW. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol. 1986;22(1):21\u20135. https:\/\/doi.org\/10.1111\/j.1365-2125.1986.tb02874.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1513_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2016-000473","volume":"3","author":"H Fares","year":"2016","unstructured":"Fares H, DiNicolantonio JJ, O\u2019Keefe JH, Lavie CJ. Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart. 2016;3(2):e000473. https:\/\/doi.org\/10.1136\/openhrt-2016-000473.","journal-title":"Open Heart"},{"issue":"4","key":"1513_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70140","volume":"13","author":"S Rognstad","year":"2025","unstructured":"Rognstad S, S\u00f8raas CL, Brunborg C, Halvorsen LV, Brobak KM, Olsen E, et al. Pharmacokinetic variability of amlodipine serum concentration and effect on blood pressure in patients treated for hypertension. Pharmacol Res Perspect. 2025;13(4):e70140. https:\/\/doi.org\/10.1002\/prp2.70140.","journal-title":"Pharmacol Res Perspect"},{"issue":"7","key":"1513_CR20","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1517\/17425255.2010.494597","volume":"6","author":"S Deppe","year":"2010","unstructured":"Deppe S, B\u00f6ger RH, Weiss J, Benndorf RA. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin Drug Metab Toxicol. 2010;6(7):863\u201371. https:\/\/doi.org\/10.1517\/17425255.2010.494597.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"1513_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2165\/00003495-200666010-00004","volume":"66","author":"AJ Battershill","year":"2006","unstructured":"Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs. 2006;66(1):51\u201383. https:\/\/doi.org\/10.2165\/00003495-200666010-00004.","journal-title":"Drugs"},{"key":"1513_CR22","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s11094-019-02062-4","volume":"53","author":"D Romodanovskii","year":"2019","unstructured":"Romodanovskii D, Goryachev D, Khokhlov A, Miroshnikov A. Investigation planning and bioequivalence evaluation of angiotensin II receptor antagonists. Pharm Chem J. 2019;53:680\u20134. https:\/\/doi.org\/10.1007\/s11094-019-02062-4.","journal-title":"Pharm Chem J"},{"issue":"7","key":"1513_CR23","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.clinthera.2012.05.010","volume":"34","author":"Y-H Noh","year":"2012","unstructured":"Noh Y-H, Lim H-S, Kim MJ, Kim YH, Choi HY, Sung HR, et al. Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy Korean male volunteers. Clin Ther. 2012;34(7):1625\u201335. https:\/\/doi.org\/10.1016\/j.clinthera.2012.05.010.","journal-title":"Clin Ther"},{"issue":"12","key":"1513_CR24","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1177\/009127000004001206","volume":"40","author":"J Stangier","year":"2000","unstructured":"Stangier J, Su CAP. Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. J Clin Pharmacol. 2000;40(12):1347\u201354. https:\/\/doi.org\/10.1177\/009127000004001206.","journal-title":"J Clin Pharmacol"},{"key":"1513_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2147\/DDDT.S156492","volume":"12","author":"WY Kang","year":"2018","unstructured":"Kang WY, Seong SJ, Ohk B, Gwon M-R, Kim BK, La S, et al. Pharmacokinetic and bioequivalence study of a telmisartan\/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects. Drug Des Dev Ther. 2018;12:545\u201353. https:\/\/doi.org\/10.2147\/DDDT.S156492.","journal-title":"Drug Des Dev Ther"},{"issue":"4","key":"1513_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1055\/s-0033-1334882","volume":"63","author":"B Gorain","year":"2013","unstructured":"Gorain B, Choudhury H, Halder D, Sarkar AK, Sarkar P, Biswas E, et al. A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. Drug Res (Stuttg). 2013;63(4):177\u201384. https:\/\/doi.org\/10.1055\/s-0033-1334882.","journal-title":"Drug Res (Stuttg)"},{"key":"1513_CR27","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.2147\/DDDT.S148534","volume":"11","author":"M Oh","year":"2017","unstructured":"Oh M, Park SE, Ghim JL, Choi YK, Shim EJ, Shin JG, et al. Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers. Drug Des Dev Ther. 2017;11:3543\u201350. https:\/\/doi.org\/10.2147\/DDDT.S148534.","journal-title":"Drug Des Dev Ther"},{"key":"1513_CR28","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.2147\/DDDT.S210364","volume":"13","author":"SJ Moon","year":"2019","unstructured":"Moon SJ, Jeon JY, Jang K, Yu KS, Lim Y, Kim MG. Pharmacokinetic interactions between telmisartan\/amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects. Drug Des Dev Ther. 2019;13:2533\u201342.","journal-title":"Drug Des Dev Ther"},{"key":"1513_CR29","unstructured":"Ministry of Food and Drug Safety (MFDS). Guideline for the Drug Equivalence Test. Bioequivalence Evaluation Division, Notice No. 2023-52; August 9, 2023 (revised). Osong: Ministry of Food and Drug Safety; 2023."},{"key":"1513_CR30","unstructured":"US Food and Drug Administration. Bioanalytical method validation: guidance for industry. Rockville: US FDA; 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed 20 Oct 2025."},{"issue":"6","key":"1513_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson M, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometr Syst Pharmacol. 2013;2(6):e50. https:\/\/doi.org\/10.1038\/psp.2013.24.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"2","key":"1513_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","volume":"35","author":"TM Post","year":"2008","unstructured":"Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35(2):185\u2013202. https:\/\/doi.org\/10.1007\/s10928-007-9081-1.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"1513_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10928-010-9177-x","volume":"38","author":"PG Baverel","year":"2011","unstructured":"Baverel PG, Savic RM, Karlsson MO. Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models. J Pharmacokinet Pharmacodyn. 2011;38(1):63\u201382. https:\/\/doi.org\/10.1007\/s10928-010-9177-x.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1513_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/DDDT.S485851","volume":"19","author":"M Tian","year":"2025","unstructured":"Tian M, Huang J, Chen Y, Jin Q, Jiang H, Shi C, et al. Pharmacokinetics and bioequivalence of two fixed-dose combination tablets of valsartan\/amlodipine (80\/5 Mg) in healthy Chinese subjects. Drug Des Dev Ther. 2025;19:11\u201322. https:\/\/doi.org\/10.2147\/DDDT.S485851.","journal-title":"Drug Des Dev Ther"},{"issue":"3","key":"1513_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/cpdd.1345","volume":"13","author":"L Tang","year":"2024","unstructured":"Tang L, Wang Y, Chen R, He Y, Liu Y, Wang N, et al. Pharmacokinetics and bioequivalence of amlodipine besylate tablet in healthy Chinese volunteers under fasting and fed conditions. Clin Pharmacol Drug Dev. 2024;13(3):259\u201364. https:\/\/doi.org\/10.1002\/cpdd.1345.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"1513_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40262-024-01471-3","volume":"64","author":"IH Jeong","year":"2025","unstructured":"Jeong IH, Ryu S, Han N, Staatz CE, Baek IH. Population pharmacokinetics of telmisartan in healthy subjects and hypertensive patients. Clin Pharmacokinet. 2025;64(2):285\u201395. https:\/\/doi.org\/10.1007\/s40262-024-01471-3.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1513_CR37","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/psp4.13154","volume":"13","author":"T Tsuchitani","year":"2024","unstructured":"Tsuchitani T, Tomaru A, Aoki Y, Ishiguro N, Tsuda Y, Sugiyama Y. Elucidating nonlinear pharmacokinetics of telmisartan: integration of target-mediated drug disposition and OATP1B3-mediated hepatic uptake in a physiologically based model. CPT Pharmacometr Syst Pharmacol. 2024;13(7):1224\u201337. https:\/\/doi.org\/10.1002\/psp4.13154.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"2","key":"1513_CR38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2133\/dmpk.dmpk-13-rg-053","volume":"29","author":"H Son","year":"2014","unstructured":"Son H, Lee D, Lim LA, Jang SB, Roh H, Park K. Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine. Drug Metab Pharmacokinet. 2014;29(2):120\u20138. https:\/\/doi.org\/10.2133\/dmpk.dmpk-13-rg-053.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1513_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.preghy.2018.01.002","volume":"11","author":"JL Morgan","year":"2018","unstructured":"Morgan JL, Kogutt BK, Meek C, Stehel EK, McIntire DD, Sheffield JS, et al. Pharmacokinetics of amlodipine besylate at delivery and during lactation. Pregnancy Hypertens. 2018;11:77\u201380. https:\/\/doi.org\/10.1016\/j.preghy.2018.01.002.","journal-title":"Pregnancy Hypertens"},{"issue":"7","key":"1513_CR40","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00228-020-03060-2","volume":"77","author":"P Courlet","year":"2021","unstructured":"Courlet P, Guidi M, Alves Saldanha S, Cavassini M, Stoeckle M, Buclin T, et al. Population pharmacokinetic modelling to quantify the magnitude of drug\u2013drug interactions between amlodipine and antiretroviral drugs. Eur J Clin Pharmacol. 2021;77(7):979\u201387. https:\/\/doi.org\/10.1007\/s00228-020-03060-2.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"1513_CR41","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1177\/0091270006289844","volume":"46","author":"JT Flynn","year":"2006","unstructured":"Flynn JT, Nahata MC, Mahan Jr, Portman RJ. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. J Clin Pharmacol. 2006;46(8):905\u201316. https:\/\/doi.org\/10.1177\/0091270006289844. (Investigators P-).","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1513_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2133\/dmpk.18.203","volume":"18","author":"S Tatami","year":"2003","unstructured":"Tatami S, Sarashina A, Yamamura N, Igarashi T, Tanigawara Y. Population pharmacokinetics of an angiotensin II receptor antagonist, telmisartan, in healthy volunteers and hypertensive patients. Drug Metab Pharmacokinet. 2003;18(3):203\u201311. https:\/\/doi.org\/10.2133\/dmpk.18.203.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"1513_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2133\/dmpk.19.15","volume":"19","author":"S Tatami","year":"2004","unstructured":"Tatami S, Yamamura N, Sarashina A, Yong CL, Igarashi T, Tanigawara Y. Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method. Drug Metab Pharmacokinet. 2004;19(1):15\u201323. https:\/\/doi.org\/10.2133\/dmpk.19.15.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"8","key":"1513_CR44","doi-asserted-by":"publisher","first-page":"659","DOI":"10.5414\/CP202744","volume":"55","author":"Q Pei","year":"2017","unstructured":"Pei Q, Yang L, Tan HY, Liu SK, Liu Y, Huang L, et al. Effects of genetic variants in UGT1A1, SLCO1B3, ABCB1, ABCC2, ABCG2, ORM1 on PK\/PD of telmisartan in Chinese patients with mild to moderate essential hypertension. Int J Clin Pharmacol Ther. 2017;55(8):659\u201365. https:\/\/doi.org\/10.5414\/CP202744.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"1513_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1365-2125.2004.02157.x","volume":"58","author":"B Green","year":"2004","unstructured":"Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58(2):119\u201333. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02157.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1513_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.tcm.2019.12.011","volume":"31","author":"JA Brooksbank","year":"2021","unstructured":"Brooksbank JA, Greene SJ, DeWald TA, Mentz RJ. Body surface area and medication dosing in patients with heart failure with reduced ejection fraction. Trends Cardiovasc Med. 2021;31(2):111\u20136. https:\/\/doi.org\/10.1016\/j.tcm.2019.12.011.","journal-title":"Trends Cardiovasc Med"},{"key":"1513_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.tiv.2017.06.014","volume":"44","author":"K Sayyed","year":"2017","unstructured":"Sayyed K, Le Vee M, Abdel-Razzak Z, Fardel O. Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Toxicol In Vitro. 2017;44:27\u201335. https:\/\/doi.org\/10.1016\/j.tiv.2017.06.014.","journal-title":"Toxicol In Vitro"},{"issue":"6","key":"1513_CR48","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.dmpk.2016.08.006","volume":"31","author":"M Takano","year":"2016","unstructured":"Takano M, Naka R, Sasaki Y, Nishimoto S, Yumoto R. Effect of cigarette smoke extract on P-glycoprotein function in primary cultured and newly developed alveolar epithelial cells. Drug Metab Pharmacokinet. 2016;31(6):417\u201324. https:\/\/doi.org\/10.1016\/j.dmpk.2016.08.006.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"1513_CR49","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.bcmd.2013.12.001","volume":"52","author":"M Clerici","year":"2014","unstructured":"Clerici M, Colombo G, Secundo F, Gagliano N, Colombo R, Portinaro N, et al. Cigarette smoke induces alterations in the drug-binding properties of human serum albumin. Blood Cells Mol Dis. 2014;52(4):166\u201374. https:\/\/doi.org\/10.1016\/j.bcmd.2013.12.001.","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"1513_CR50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00003088-200544010-00002","volume":"44","author":"MM Cotreau","year":"2005","unstructured":"Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44(1):33\u201360. https:\/\/doi.org\/10.2165\/00003088-200544010-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1513_CR51","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/cpt.1928","volume":"108","author":"P Hirvensalo","year":"2020","unstructured":"Hirvensalo P, Tornio A, Launiainen T, Paile-Hyv\u00e4rinen M, Tapaninen T, Neuvonen M, et al. UGT1A3 and sex are major determinants of telmisartan pharmacokinetics\u2014a comprehensive pharmacogenomic study. Clin Pharmacol Ther. 2020;108(4):885\u201395. https:\/\/doi.org\/10.1002\/cpt.1928.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1513_CR52","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1177\/0091270008317847","volume":"48","author":"S Rohatagi","year":"2008","unstructured":"Rohatagi S, Carrothers TJ, Kshirsagar S, Khariton T, Lee J, Salazar D. Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil. J Clin Pharmacol. 2008;48(7):823\u201336. https:\/\/doi.org\/10.1177\/0091270008317847.","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01513-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01513-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01513-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:35:19Z","timestamp":1770179719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01513-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1513"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01513-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hee Kyung Hwang, Bo Ram Kim, and Hyo Cheol Kim are employees of Daewoo Pharm Co., Ltd. Christine Staatz is an Editorial Board member of Clinical Drug Investigation. Christine Staatz was not involved in the selection of peer reviewers for this manuscript nor in any of the subsequent editorial decisions. The other authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"The study protocol was approved by the Institutional Review Board of H-plus Yangji Hospital (approval no. HYJ 2021-05-001) and was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and the Korean Good Clinical Practice guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The model code that supports the findings of this study is available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All participants provided written informed consent prior to enrollment in the original bioequivalence study. As this population pharmacokinetic analysis was conducted using de-identified data obtained from that completed study, additional informed consent was not required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Eunji Yu: Data curation, formal analysis, investigation, methodology, and writing\u2014original draft. Hee Kyung Hwang: Conceptualization, data curation, formal analysis, investigation, methodology, and writing\u2014original draft. Bo Ram Kim: Data curation, formal analysis, validation, and writing\u2014review and editing. Hyo Cheol Kim: Data curation, validation, and writing\u2014review and editing. Christine E. Staatz: Investigation, methodology, supervision, validation, and writing\u2014review and editing. Seh-Hyon Song: Conceptualization, formal analysis, and writing\u2014review and editing. Woojin Jung: Formal analysis, investigation, methodology, validation, and writing\u2014review and editing. Min-Soo Kim: Conceptualization, formal analysis, supervision, and writing\u2014review and editing. In-hwan Baek: Conceptualization, funding acquisition, investigation, methodology, and writing\u2014original draft supervision. All authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}